Literature DB >> 15593257

Prenatal diagnosis of absence of the septum pellucidum associated with septo-optic dysplasia.

C Lepinard1, R Coutant, F Boussion, D Loisel, B Delorme, F Biquard, D Bonneau, A Guichet, P Descamps.   

Abstract

Septo-optic dysplasia (SOD; De Morsier syndrome) is a rare congenital disorder characterized by the absence of the septum pellucidum (SP), hypoplasia of the optic chiasma and nerves, and various types of hypothalamic-pituitary dysfunction. We report on two fetuses with absence of the SP diagnosed by ultrasound examination at 29 and 30 gestational weeks. In the first case the diagnosis of SOD was suspected in utero and confirmed postnatally; to the best of our knowledge this is the first report of the prenatal diagnosis of SOD. In the second case absence of the SP appeared to be isolated and no visual or endocrine impairment were detected after birth. Copyright (c) 2004 ISUOG.

Entities:  

Mesh:

Year:  2005        PMID: 15593257     DOI: 10.1002/uog.1807

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  3 in total

1.  Outcome of fetuses with cerebral ventriculomegaly and septum pellucidum leaflet abnormalities.

Authors:  Yi Li; Rakhee K Sansgiri; Judy A Estroff; Tejas S Mehta; Tina Y Poussaint; Richard L Robertson; Caroline D Robson; Henry A Feldman; Carol Barnewolt; Deborah Levine
Journal:  AJR Am J Roentgenol       Date:  2011-01       Impact factor: 3.959

2.  Absence of the septum pellucidum associated with a midline fornical nodule and ventriculomegaly: a report of two cases.

Authors:  Yi Kyeong Chun; Hye Sun Kim; Sung Ran Hong; Je G Chi
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

3.  Long-term postnatal outcome of fetuses with prenatally suspected septo-optic dysplasia.

Authors:  S Shinar; S Blaser; D Chitayat; T Selvanathan; V Chau; P Shannon; S Agrawal; G Ryan; V Pruthi; S P Miller; P Krishnan; T Van Mieghem
Journal:  Ultrasound Obstet Gynecol       Date:  2020-09       Impact factor: 7.299

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.